Voyageur Pharmaceuticals Strengthens Capital Position and Prepares for Market Expansion

Voyageur Pharmaceuticals ( (TSE:VM) ) has provided an announcement.

Voyageur Pharmaceuticals has successfully secured $687,099 through the exercise of 5,725,829 share purchase warrants, indicating strong investor support and streamlining its capitalization table. The company achieved significant milestones in 2024, including a CAD $2.7 million sales contract and a Letter of Intent with a major multinational firm, positioning it for further growth and leadership in the radiology drug market by launching new products and preparing for FDA applications in 2025.

More about Voyageur Pharmaceuticals

Voyageur Pharmaceuticals Ltd., a Canadian public company listed on the TSXV, is focused on the development of barium and iodine Active Pharmaceutical Ingredients (API) and aims to become a significant player in the medical imaging industry by vertically integrating the barium and iodine contrast markets. The company has developed five barium contrast products with Health Canada licenses and is working on producing its own barium, iodine, and new endohedral fullerene drugs.

YTD Price Performance: -5.00%

Average Trading Volume: 19,114

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $17.26M

See more data about VM stock on TipRanks’ Stock Analysis page.